vs
MESA LABORATORIES INC（MLAB）与RCI HOSPITALITY HOLDINGS, INC.（RICK）财务数据对比。点击上方公司名可切换其他公司
RCI HOSPITALITY HOLDINGS, INC.的季度营收约是MESA LABORATORIES INC的1.1倍（$70.9M vs $65.1M），MESA LABORATORIES INC净利率更高（5.6% vs -7.8%，领先13.3%），MESA LABORATORIES INC同比增速更快（3.6% vs -3.1%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $11.5M），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs -2.0%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
RCI Hospitality控股通过子公司经营脱衣舞俱乐部、夜总会、运动酒吧与餐厅，同时还运营一家为成人俱乐部行业提供服务的传媒会展企业。公司于1995年完成首次公开募股上市，目前在纳斯达克全球市场挂牌交易。
MLAB vs RICK — 直观对比
营收规模更大
RICK
是对方的1.1倍
$65.1M
营收增速更快
MLAB
高出6.8%
-3.1%
净利率更高
MLAB
高出13.3%
-7.8%
自由现金流更多
MLAB
多$6.5M
$11.5M
两年增速更快
MLAB
近两年复合增速
-2.0%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $70.9M |
| 净利润 | $3.6M | $-5.5M |
| 毛利率 | 64.2% | — |
| 营业利润率 | 12.2% | -0.7% |
| 净利率 | 5.6% | -7.8% |
| 营收同比 | 3.6% | -3.1% |
| 净利润同比 | 316.6% | -2354.9% |
| 每股收益（稀释后） | $0.65 | $-0.60 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABRICK
| Q4 25 | $65.1M | — | ||
| Q3 25 | $60.7M | $70.9M | ||
| Q2 25 | $59.5M | $71.1M | ||
| Q1 25 | $62.1M | $65.9M | ||
| Q4 24 | $62.8M | $71.5M | ||
| Q3 24 | $57.8M | $73.2M | ||
| Q2 24 | $58.2M | $76.2M | ||
| Q1 24 | $58.9M | $72.3M |
净利润MLABRICK
| Q4 25 | $3.6M | — | ||
| Q3 25 | $2.5M | $-5.5M | ||
| Q2 25 | $4.7M | $4.1M | ||
| Q1 25 | $-7.1M | $3.2M | ||
| Q4 24 | $-1.7M | $9.0M | ||
| Q3 24 | $3.4M | $244.0K | ||
| Q2 24 | $3.4M | $-5.2M | ||
| Q1 24 | $-254.6M | $774.0K |
毛利率MLABRICK
| Q4 25 | 64.2% | — | ||
| Q3 25 | 61.5% | — | ||
| Q2 25 | 62.0% | — | ||
| Q1 25 | 61.8% | — | ||
| Q4 24 | 63.3% | — | ||
| Q3 24 | 61.3% | — | ||
| Q2 24 | 64.0% | — | ||
| Q1 24 | 62.1% | — |
营业利润率MLABRICK
| Q4 25 | 12.2% | — | ||
| Q3 25 | 7.8% | -0.7% | ||
| Q2 25 | 5.1% | 12.2% | ||
| Q1 25 | 2.4% | 12.4% | ||
| Q4 24 | 9.2% | 19.5% | ||
| Q3 24 | 6.1% | 4.8% | ||
| Q2 24 | 9.6% | -3.3% | ||
| Q1 24 | -460.6% | 6.4% |
净利率MLABRICK
| Q4 25 | 5.6% | — | ||
| Q3 25 | 4.1% | -7.8% | ||
| Q2 25 | 8.0% | 5.7% | ||
| Q1 25 | -11.4% | 4.9% | ||
| Q4 24 | -2.7% | 12.6% | ||
| Q3 24 | 5.9% | 0.3% | ||
| Q2 24 | 5.8% | -6.9% | ||
| Q1 24 | -432.2% | 1.1% |
每股收益（稀释后）MLABRICK
| Q4 25 | $0.65 | — | ||
| Q3 25 | $0.45 | $-0.60 | ||
| Q2 25 | $0.85 | $0.46 | ||
| Q1 25 | $-1.30 | $0.36 | ||
| Q4 24 | $-0.31 | $1.01 | ||
| Q3 24 | $0.63 | $0.04 | ||
| Q2 24 | $0.62 | $-0.56 | ||
| Q1 24 | $-47.26 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $33.7M |
| 总债务越低越好 | $68.4M | $238.2M |
| 股东权益账面价值 | $186.7M | $261.1M |
| 总资产 | $434.8M | $596.9M |
| 负债/权益比越低杠杆越低 | 0.37× | 0.91× |
8季度趋势，按日历期对齐
现金及短期投资MLABRICK
| Q4 25 | $29.0M | — | ||
| Q3 25 | $20.4M | $33.7M | ||
| Q2 25 | $21.3M | $29.3M | ||
| Q1 25 | $27.3M | $32.7M | ||
| Q4 24 | $27.3M | $34.7M | ||
| Q3 24 | $24.3M | $32.4M | ||
| Q2 24 | $28.5M | $34.9M | ||
| Q1 24 | $28.2M | $20.0M |
总债务MLABRICK
| Q4 25 | $68.4M | — | ||
| Q3 25 | $69.4M | $238.2M | ||
| Q2 25 | $70.3M | $243.8M | ||
| Q1 25 | $71.3M | $244.1M | ||
| Q4 24 | $72.2M | — | ||
| Q3 24 | $73.1M | $241.1M | ||
| Q2 24 | $74.1M | — | ||
| Q1 24 | — | — |
股东权益MLABRICK
| Q4 25 | $186.7M | — | ||
| Q3 25 | $178.5M | $261.1M | ||
| Q2 25 | $172.5M | $269.5M | ||
| Q1 25 | $159.8M | $268.8M | ||
| Q4 24 | $155.2M | $269.0M | ||
| Q3 24 | $161.5M | $263.4M | ||
| Q2 24 | $150.7M | $271.2M | ||
| Q1 24 | $145.4M | $285.8M |
总资产MLABRICK
| Q4 25 | $434.8M | — | ||
| Q3 25 | $430.4M | $596.9M | ||
| Q2 25 | $435.7M | $597.4M | ||
| Q1 25 | $433.3M | $589.8M | ||
| Q4 24 | $433.3M | $586.2M | ||
| Q3 24 | $454.1M | $584.4M | ||
| Q2 24 | $440.4M | $601.0M | ||
| Q1 24 | $446.8M | $609.9M |
负债/权益比MLABRICK
| Q4 25 | 0.37× | — | ||
| Q3 25 | 0.39× | 0.91× | ||
| Q2 25 | 0.41× | 0.90× | ||
| Q1 25 | 0.45× | 0.91× | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.45× | 0.92× | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | $13.7M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | $11.5M |
| 自由现金流率自由现金流/营收 | 27.7% | 16.2% |
| 资本支出强度资本支出/营收 | 1.1% | 3.2% |
| 现金转化率经营现金流/净利润 | 5.17× | — |
| 过去12个月自由现金流最近4个季度 | $37.9M | $34.9M |
8季度趋势，按日历期对齐
经营现金流MLABRICK
| Q4 25 | $18.8M | — | ||
| Q3 25 | $8.2M | $13.7M | ||
| Q2 25 | $1.9M | $13.8M | ||
| Q1 25 | $12.7M | $8.5M | ||
| Q4 24 | $18.1M | $13.3M | ||
| Q3 24 | $5.3M | $15.7M | ||
| Q2 24 | $10.7M | $15.8M | ||
| Q1 24 | $12.9M | $10.8M |
自由现金流MLABRICK
| Q4 25 | $18.0M | — | ||
| Q3 25 | $7.1M | $11.5M | ||
| Q2 25 | $884.0K | $10.1M | ||
| Q1 25 | $11.9M | $5.7M | ||
| Q4 24 | $17.3M | $7.6M | ||
| Q3 24 | $3.5M | $10.3M | ||
| Q2 24 | $9.9M | $9.3M | ||
| Q1 24 | $12.3M | $3.2M |
自由现金流率MLABRICK
| Q4 25 | 27.7% | — | ||
| Q3 25 | 11.7% | 16.2% | ||
| Q2 25 | 1.5% | 14.2% | ||
| Q1 25 | 19.2% | 8.6% | ||
| Q4 24 | 27.6% | 10.6% | ||
| Q3 24 | 6.0% | 14.0% | ||
| Q2 24 | 16.9% | 12.3% | ||
| Q1 24 | 21.0% | 4.4% |
资本支出强度MLABRICK
| Q4 25 | 1.1% | — | ||
| Q3 25 | 1.8% | 3.2% | ||
| Q2 25 | 1.7% | 5.2% | ||
| Q1 25 | 1.2% | 4.3% | ||
| Q4 24 | 1.3% | 8.0% | ||
| Q3 24 | 3.1% | 7.3% | ||
| Q2 24 | 1.5% | 8.4% | ||
| Q1 24 | 0.9% | 10.6% |
现金转化率MLABRICK
| Q4 25 | 5.17× | — | ||
| Q3 25 | 3.32× | — | ||
| Q2 25 | 0.40× | 3.40× | ||
| Q1 25 | — | 2.65× | ||
| Q4 24 | — | 1.48× | ||
| Q3 24 | 1.54× | 64.14× | ||
| Q2 24 | 3.17× | — | ||
| Q1 24 | — | 14.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
RICK
| Transferred At Point In Time | $60.8M | 86% |
| Food And Merchandise | $10.4M | 15% |
